Related Experiment Video
Updated: Nov 3, 2025
Author Spotlight: Studying Host-Virus Interactions with Pseudotyped Viruses
Published on: November 21, 2023
Vaccines for COVID-19: An Overview.
Thomas F Lang1, Robert M Eber2, Michael S Reddy3
1Department of Radiology and Biomedical Imaging, School of Medicine, University of California San Francisco, San Francisco, California.
The rapid development of COVID-19 vaccines utilized innovative platforms, with many candidates in trials or emergency use within a year. This review summarizes leading vaccine performance and discusses challenges like virus mutations and spread.
Area of Science:
- Virology
- Immunology
- Vaccinology
Background:
- The COVID-19 pandemic necessitated rapid scientific advancement.
- Unprecedented speed in research for virus biology, immune response, testing, therapeutics, and vaccines.
- Over 40 vaccine candidates emerged within a year of the global outbreak.
Purpose of the Study:
- To summarize the characteristics and performance of leading COVID-19 vaccines.
- To discuss the impact of virus mutations on vaccine efficacy.
- To address the role of asymptomatic spread in pandemic control.
Main Methods:
- Review of scientific literature on COVID-19 vaccine development.
- Analysis of data from Phase 3 trials and emergency use authorizations.
- Examination of virological and epidemiological studies on SARS-CoV-2.
Main Results:
- Multiple innovative vaccine platforms were employed.
- 21 vaccine candidates were in Phase 3 trials or under emergency use.
- Leading vaccines demonstrated varying efficacy and performance characteristics.
Conclusions:
- The rapid development of COVID-19 vaccines represents a significant scientific achievement.
- Virus mutations and asymptomatic spread pose challenges to global vaccine deployment.
- Achieving herd immunity and restoring normality depend on continued research and equitable vaccine distribution.
More Related Videos
08:07A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain
Published on: July 25, 2022
08:41Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
Published on: November 5, 2021
Related Concept Videos
01:51Vaccinations
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:29Microorganisms in Medicine and Therapeutics
01:29Immune Response Against Viral Pathogens
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
02:50Conjugated Proteins
Nucleoproteins are protein complexes that contain nucleic acids, categorized as deoxyribonucleoproteins (DNPs) or ribonucleoproteins (RNPs) respectively. The nucleosome is a typical example of a DNP where nuclear DNA is associated with histone proteins. The major antigen for the Covid-19 virus SARS-CoV is an RNP that is critical...
01:28Preclinical Development: Overview